Expanding access to quality medical products
Patients have a right to quality-assured medical products, no matter where they live.

As a science-based, international nonprofit organization, we help increase the supply of safe and effective medicines, vaccines, and trusted diagnostics. USP strengthens health systems at local, regional, and global levels and delivers end-to-end pharmaceutical services that champion equitable access to quality medical products. Our work improves supply chain resilience, protects patients from poor-quality medicines, and combats antimicrobial resistance.

200 years building trust in the supply of safe, quality-assured medical products.

2 billion people impacted by our work to improve quality across the pharmaceutical supply chain.

Patients have a right to quality-assured medical products, no matter where they live.
Our global health programs have reached more than 90 countries across Africa, Asia, and North and South America to strengthen health systems and supply chains.
Expanding manufacturing capacity
Increasing the supply of medical products builds supply chain resilience and improves health equity. We expand manufacturing capacity of raw materials, active pharmaceutical ingredients, and finished products to improve access to medicines and vaccines worldwide.

Procuring for quality
Medical product procurement is often driven by pressures to purchase lowest cost products with varying degrees of oversight. We implement best-in-class procurement procedures, analyze risk, and apply key performance metrics to assure quality in procurement.

Ensuring quality across the supply chain

Our expertise

Advancing regulatory maturity
Regulatory systems are vital to ensuring quality products reach patients faster. We work to advance regulatory maturity, improve pandemic preparedness, and support introduction of new products, including those for emergency use.

Strengthening laboratories
Clinical and pharmaceutical laboratories protect patients and enhance health security. We bolster laboratory networks to ensure test results are accurate, improve treatment decisions, empower regulators to act, and combat antimicrobial resistance.

Improving patient safety
Assuring the safety of medicines doesn’t stop once they’re approved for use. We strengthen pharmacovigilance programs to optimize treatment regimens, support data-driven decision-making, and promote the continued safety of medical products.

Harnessing data and analytics
Robust data systems help stakeholders make faster decisions that promote health equity, contain the spread of disease, and increase supply chain resilience. We couple data, technology, and analytics to enable decision-makers to act quickly and efficiently.
This work would not be possible without the generous support of donors like the Australian Department of Foreign Affairs and Trade (DFAT), Global Fund, U.S. Agency for International Development (USAID), World Health Organization (WHO), and others.

Building an enabling ecosystem for pharmaceutical manufacturing

We expand pharmaceutical manufacturing in low- and middle-income countries to advance health equity where it’s needed most. But making sustainable progress means our work extends beyond manufacturers. We cultivate an enabling ecosystem for expanded production by strengthening regulatory systems, advancing national pharmaceutical strategies, building a robust local workforce, analyzing business cases, and convening private and public sector stakeholders to resolve bottlenecks.

Driving innovation through data and research

Exploring new technologies, answering vital research questions, and applying data in new ways are key to USP’s drive to advance innovation. We promote solutions that:

- Signal possible medicine shortages through tools like our Medicine Supply Map.
- Spur adoption of advanced technologies, such as continuous manufacturing, to create production efficiencies.
- Enable data-driven policies to combat antimicrobial resistance through our Quality Institute research.

Our impact

90+ countries supported to strengthen health systems and medicine supply chains.

118 manufacturers supported and 40+ medical products approved by WHO or a stringent regulatory authority.

47 national medicine regulatory agencies strengthened to deliver key functions like dossier evaluation, market authorization, and risk-based post-marketing surveillance.

91 control or clinical laboratories strengthened, including 37 that received global accreditation.
We strengthen the global supply chain so that the medicines, vaccines, and diagnostics patients rely on are available when needed and work as expected.